Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1997 Jul;121(6):1075–1080. doi: 10.1038/sj.bjp.0701237

Modulation of synovial blood flow by the calcitonin gene-related peptide (CGRP) receptor antagonist, CGRP(8–37)

Lorraine McMurdo 1,*, J C Lockhart 1, W R Ferrell 1
PMCID: PMC1564796  PMID: 9249241

Abstract

  1. The effect of the calcitonin gene-related peptide (CGRP) receptor antagonist, CGRP(8–37) on blood flow in the knee joint of the anaesthetized rat was investigated.

  2. Synovial blood flow in both exposed and intact, skin-covered knees was measured by laser Doppler perfusion imaging.

  3. Topical application of CGRP(8–37) caused a dose-dependent fall in synovial blood flow in the exposed knee joint of the rat. At low (1.5 nmol) doses of CGRP(8–37) there was no significant effect on synovial blood flow. In rats treated with 7.5 nmol CGRP(8–37) there was a fall in synovial blood flow (maximum effect at 10 min: −28.8±4.6%; n=7), which returned to resting levels within 30 min. The highest dose (15 nmol) of antagonist used in this study caused a marked (maximum at 10 min: −35.6±9.3%; n=8), and prolonged (up to 30 min) fall in blood flow.

  4. Ten days after surgical denervation, CGRP(8–37) (15 nmol, topical) had no significant effect on blood flow in the rat exposed knee joint (change in flux at 10 min: −5.1±3.6%; n=4). This suggests that CGRP(8–37) acts selectively to antagonize the actions of a neurally derived product, probably CGRP, on the rat synovial vasculature.

  5. In skin-covered knee joints, intra-articular injection of CGRP(8–37) (15 nmol; bolus) elicited a significant fall in synovial blood flow (maximum effect at 10 min: −15.5±5.8%; n=6).

  6. CGRP (0.01, 0.1 or 1.0 nmol; topical) caused a dose-dependent increase in exposed knee joint blood flow, which was attenuated by co-administration of 1.5 nmol CGRP(8–37). For example, 1 nmol CGRP elicited a peak increase in flux at 10 min of 94.7±31.8% (n=8) and 28.8±8.9% (n=7) in the absence and presence of CGRP(8–37), respectively. The vasodilator responses induced by acetylcholine (ACh) (10 nmol, topical; n=4–5) or sodium nitroprusside (SNP) (10 nmol, topical; n=4–5) were unaltered in the presence of CGRP(8–37) (1.5 nmol, topical).

  7. Thus, the CGRP receptor antagonist CGRP(8–37) elicits vasoconstriction in the rat synovium. This suggests that the endogenous, basal release of CGRP may play a physiological role in the regulation of blood flow in the rat knee joint.

Keywords: Calcitonin gene-related peptide (CGRP), calcitonin gene-related peptide receptor antagonist (CGRP8–37), rat synovial blood flow

Full Text

The Full Text of this article is available as a PDF (348.6 KB).


Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES